Other substances

Atorvastatin

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
16
 AI-suggested references
9
 Clinical trials

General information

Atorvastatin is a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells (NCIt).

 

Structure image - Atorvastatin

Supporting references

Link Tested on Impact factor Notes Publication date
Effect of statins on SARS-CoV-2 infection
Preprint 		Patients

a mild beneficial effect on COVID-19 outcome

 Jul/14/2020
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
Patients 21.57

A retrospective cohort study of in-hospital statin use among COVID-19 patients. Lower risk of all-cause mortality. Lower use of invasive mechanical ventilation, ARDS prevalence and ICU admission. Possible due to inflammatory response amelioration. Dosage - daily equivalent dose of statin, median 20 mg. Endpoints - 28-day all-cause mortality; ICU admission; use of invasive mechanical ventilation; ARDS incidence. Sample size 1,014 patients (1,219 statins + 12,762 control).

 Aug/04/2020

AI-suggested references

Link Publication date
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
Jan/07/2022
Associastion of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19.
Aug/10/2020
Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial
Mar/22/2022
Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex
Oct/07/2021
Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching
Feb/17/2022
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial
Feb/24/2021
Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients
Oct/15/2021
Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; a retrospective cohort study
Jul/05/2021
SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets.
Feb/18/2021
Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence
Nov/30/2021
Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients
Nov/29/2021
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Sep/09/2021
Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 in vitro
Mar/18/2022
Statins and the COVID-19 main protease: in silico evidence on direct interaction
Apr/25/2020
The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction
Jul/12/2021
Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations.
Jul/06/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04631536 Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC Active, not recruiting Phase 3 Jan/10/2021 Jul/01/2022
  • Alternative id - Lebanese American University
  • Interventions - Drug: Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - LAUMCRH, Beirut, Lebanon
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 42
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Improvement|Need for ICU admission or invasive mechanical ventilation|All cause mortality|Occurrence of side effects
NCT04466241 Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Recruiting Phase 2|Phase 3 Nov/27/2020 Mar/26/2021
  • Alternative id - ANRS COV01 INTENSE COV
  • Interventions - Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Drug: Telmisartan 40Mg Oral Tablet|Drug: Atorvastatin 20 Mg Oral Tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 294
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11|Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28|Kinetics of SARS-CoV-2 viral load|Death rate at Day 11 and Day 28|All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28|Time to hospital discharge|Duration of oxygen supplementation|Prevalence of grade III or IV adverse events|Residual concentration of lopinavir, telmisartan and atorvastatin|Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes)|Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2)|Proportion of patients with good results according to HIV status|Number of contact cases infected by COVID-19 at Day 28
NCT04904536 Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy Not yet recruiting Phase 3 Oct/11/2021 Jun/01/2023
  • Alternative id - X21-0113
  • Interventions - Drug: Atorvastatin|Other: Standard Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The George Institute for Global Health, Sydney, New South Wales, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Neurological Recovery|Brain Imaging
NCT04801940 HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID) Recruiting Phase 3 May/19/2021 Jan/31/2024
  • Alternative id - A095848
  • Interventions - Drug: Apixaban|Drug: Atorvastatin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Addenbrookes Hospital, Cambridge, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2631
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital free survival.|All-cause mortality|Hospital readmission after discharge from index hospital admission|Suspected Serious Adverse Reactions|FACIT-Fatigue|Modified MRC Dyspnoea Scale|COVID-19 core outcome measure for recovery|Patient Health Questionnaire-2 (PHQ-2)|Generalized Anxiety Disorder-2 (GAD-2)|PTSD Checklist (PCL-2)|Quality of life using the EQ5D-5L|Intervention tolerability using the FACT-GP5|Additional disease specific systemic symptoms
NCT04952350 Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT Active, not recruiting Phase 3 Aug/14/2021 Apr/01/2022
  • Alternative id - R.21.04.1300.R1
  • Interventions - Drug: Atorvastatin 40 Mg Oral Tablet|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mansoura University Hospitals, Mansoura, Aldakahlia, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 220
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - mortality|incidence of invasive mechanical ventilation (IMV)|duration of invasive mechanical ventilation (IMV)|Time to clinical improvement|serious adverse effects|Intensive Care length of stay|acute kidney injury|status at hospital discharge|Hospital length of stay
NCT04486508 Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 Completed Phase 3 Jul/30/2020 Jul/05/2021
  • Alternative id - 99060
  • Interventions - Drug: intermediate dose Enoxaparin/ unfractionated heparin|Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin|Drug: Atorvastatin 20mg|Drug: Matched placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Masih Daneshvari Hospital, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - a composite of acute VTE, arterial thrombosis, treatment with ECMO, or all-cause mortality|Rate of all-cause mortality|Rate of objectively-confirmed VTE|Ventilator free days|Rate of major bleeding|Rate of clinically-relevant non-major bleeding|Rate of severe thrombocytopenia|Rate of rise in liver enzymes|Clinically-diagnosed myopathy|Objectively-confirmed arterial thrombosis
NCT04380402 Atorvastatin as Adjunctive Therapy in COVID-19 Recruiting Phase 2 Jun/25/2020 May/08/2022
  • Alternative id - MountAuburn
  • Interventions - Drug: Atorvastatin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mount Auburn Hospital, Cambridge, Massachusetts, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death|Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement|Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement|Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7
NCT04333407 Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. Recruiting Not Applicable Apr/03/2020 Mar/30/2021
  • Alternative id - 20HH5868
  • Interventions - Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Charing Cross Hospital, London, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 3170
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate
NCT04900155 Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19 Recruiting Not Applicable Nov/20/2020 May/01/2022
  • Alternative id - PSU/T-487
  • Interventions - Drug: Atorvastatin 80mg|Drug: Atorvastatin-Ezetimibe
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Valentin Oleynikov, Penza, Russian Federation
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 30 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Lipid profile assessment|Assessment of ventricular rhythm disturbances|Electrical instability and autonomic regulation of heart rate|Left ventricular systolic function|Left ventricular myocardial deformation (strain, strain rate)|Number of Participants with major cardiovascular events
Export (.csv)